Cowen, Deutsche Bank assist; proceeds fund general corporate purposes
By Devika Patel
Knoxville, Tenn., June 27 - Omeros Corp. said it priced a $30 million public sale of stock with a 15% greenshoe. The deal was announced on Tuesday.
The company will sell 2,926,830 common shares at $10.25 apiece. The price per share is a 22.64% discount to the June 26 closing share price of $13.25.
Cowen and Co. and Deutsche Bank Securities are the joint bookrunning managers. Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences are the co-managers.
Settlement is expected on July 2.
Proceeds will be used for general corporate purposes, including the clinical development of OMS302 and OMS103HP, research and development, preclinical studies and clinical trials, capital expenditures, working capital and advancing product candidates towards commercialization.
Omeros is a biopharmaceutical company based in Seattle.
| Issuer: | Omeros Corp.
|
| Issue: | Common shares
|
| Amount: | $30 million
|
| Greenshoe: | 15%
|
| Shares: | 2,926,830
|
| Price: | $10.25
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co. and Deutsche Bank Securities
|
| Announcement date: | June 26
|
| Pricing date: | June 27
|
| Settlement date: | July 2
|
| Stock symbol: | Nasdaq: OMER
|
| Stock price: | $13.25 at close June 26
|
| Market capitalization: | $241.8 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
